baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Regeneron Pharmaceuticals Inc./ US75886F1075 /

5/20/2024 7:57:43 AM	Chg. +10.8000	Volume	Bid8:00:06 PM	Ask8:00:06 PM	Market Capitalization	Dividend Y.	P/E Ratio
903.4000EUR	+1.21%	- Turnover: -	900.4000Bid Size: 90	909.0000Ask Size: 90	100.2 bill.EUR	-	-

GlobeNewswire 5/20 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 5/20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 5/20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 5/20 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...

GlobeNewswire 5/17 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 5/14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 5/14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire 5/13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 5/10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 5/9 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 5/8 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 5/7 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 5/6 Regeneron Announces Investor Conference Presentations

GlobeNewswire 5/2 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 4/29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 4/26 Medigene AG reports Financial Results and Business Update for Q1 2024

GlobeNewswire 4/25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 4/24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 4/23 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 4/22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 4/18 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...

GlobeNewswire 4/18 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...

GlobeNewswire 4/16 Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire 4/16 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 4/15 Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation

Regeneron Pharmaceuticals Inc./ US75886F1075 /

If you wish to receive reply to your feedback, please provide your email address.